Predictive factors for response to peginterferon-alpha and ribavirin treatment of chronic HCV infection in patients aged 65 years and more.

scientific article published on 18 September 2010

Predictive factors for response to peginterferon-alpha and ribavirin treatment of chronic HCV infection in patients aged 65 years and more. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1007/S10620-010-1408-X
P698PubMed publication ID20848200

P50authorEdoardo G. GianniniQ41633423
P2093author name stringVincenzo Savarino
Antonino Picciotto
Monica Basso
P2860cites workPersistent infection of hepatitis C virus in the elderly: a clinical and quantitative pathological study of autopsy casesQ42994839
Chronic liver disease related to hepatitis C virus: age of patients seems to be a determinant of severity independently of viral genotype.Q42998094
The effect of age on response to therapy with peginterferon alpha plus ribavirin in a cohort of patients with chronic HCV hepatitis including subjects older than 65 yr.Q43036906
Clinical outcomes after transfusion-associated hepatitis C.Q44746801
Hepatitis C: Should antiviral therapy be offered to elderly patients?Q50561889
Efficacy of peginterferon-alpha-2b plus ribavirin in patients aged 65 years and older with chronic hepatitis C.Q50562605
Are elderly patients poor candidates for pegylated interferon plus ribavirin in the treatment of chronic hepatitis C?Q50576728
Epidemiology of hepatitis C virus infectionQ22305500
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infectionQ27860901
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trialQ27860949
An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study GroupQ29614898
Histological grading and staging of chronic hepatitisQ29619625
The prevalence of hepatitis C virus infection in the United States, 1999 through 2002Q29619974
Elderly patients are at greater risk of cytopenia during antiviral therapy for hepatitis C.Q33372766
Hepatitis C in 6,865 patients 65 yr or older: a severe and neglected curable disease?Q34537738
Monitoring of viral levels during therapy of hepatitis C.Q34984089
Appendix: The National Institutes of Health Consensus Development Conference Management of Hepatitis C 2002.Q35105731
Ten year incidence of HCV infection in northern Italy and frequency of spontaneous viral clearance.Q35595775
Practical use of hepatitis C virus kinetics monitoring in the treatment of chronic hepatitis C.Q36980745
The changing epidemiology of hepatitis C virus infection in EuropeQ37006042
Efficacy and safety of pegylated interferon combined with ribavirin for the treatment of older patients with chronic hepatitis C.Q38376150
Projecting future complications of chronic hepatitis C in the United StatesQ40594872
Hepatitis C virus infection and related chronic liver disease in a resident elderly population: the Silea StudyQ42990661
P433issue11
P921main subjectribavirinQ421862
P304page(s)3193-3199
P577publication date2010-09-18
P1433published inDigestive Diseases and SciencesQ15716711
P1476titlePredictive factors for response to peginterferon-alpha and ribavirin treatment of chronic HCV infection in patients aged 65 years and more.
P478volume55

Reverse relations

cites work (P2860)
Q37879193Antiviral therapy: why does it fail in HCV-related chronic hepatitis?
Q50550604Efficacy and safety of ribavirin plus pegylated interferon alfa in geriatric patients with chronic hepatitis C.
Q38160178Predictors for dose reduction of antiviral therapy in older patients infected with hepatitis C virus: a meta-regression analysis
Q40707649Response to peginterferon-alpha 2b and ribavirin in Japanese patients with chronic hepatitis C genotype 1.
Q34190390The effect of pegylated interferon-alpha2b and ribavirin combination therapy for chronic hepatitis C infection in elderly patients
Q33635003Treatment of hepatitis C virus infection and associated vascular complications: a literature review

Search more.